Giuseppe Orlando to Aged
This is a "connection" page, showing publications Giuseppe Orlando has written about Aged.
Connection Strength
0.236
-
Orlando G, Baiocchi L, Cardillo A, Iaria G, De Liguori Carino N, De Liguori N, De Luca L, Ielpo B, Tariciotti L, Angelico M, Tisone G. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl. 2007 Jan; 13(1):46-54.
Score: 0.030
-
Orlando G, Blairvacq JS, Otte JB, Goffette P, Ciccarelli O, Sempoux C, Lerut J. Successful treatment of recurrent cholangitis after adult liver transplantation with a Tsuchida antireflux valve. Transplantation. 2004 Apr 27; 77(8):1307-8.
Score: 0.025
-
Rogers J, Farney AC, Orlando G, Harriman D, Reeves-Daniel A, Jay CL, Doares W, Kaczmorski S, Gautreaux MD, Stratta RJ. Dual Kidney Transplantation from Donors at the Extremes of Age. J Am Coll Surg. 2019 04; 228(4):690-705.
Score: 0.017
-
Ponte A, Orlando G, Siccardi GL. The True Ponte Osteotomy: By the One Who Developed It. Spine Deform. 2018 01; 6(1):2-11.
Score: 0.016
-
Khan MA, El-Hennawy H, Farney AC, Rogers J, Orlando G, Reeves-Daniel A, Palanisamy A, Gautreaux M, Iskandar S, Doares W, Kaczmorski S, Stratta RJ. Analysis of local versus imported expanded criteria donor kidneys: A single-center experience with 497 ECD kidney transplants. Clin Transplant. 2017 08; 31(8).
Score: 0.015
-
Stratta RJ, Farney AC, Palanisamy A, Rogers J, Orlando G, Reeves-Daniel A. Single-Center Experience with Deceased Donor Kidney Transplantation in 114 Individuals Aged 70 and Older in the New Millennium. J Am Geriatr Soc. 2016 11; 64(11):e219-e221.
Score: 0.015
-
Stratta RJ, Farney AC, Orlando G, Farooq U, Al-Shraideh Y, Palanisamy A, Reeves-Daniel A, Doares W, Kaczmorski S, Gautreaux MD, Iskandar SS, Hairston G, Brim E, Mangus M, El-Hennawy H, Khan M, Rogers J. Dual kidney transplants from adult marginal donors successfully expand the limited deceased donor organ pool. Clin Transplant. 2016 Apr; 30(4):380-92.
Score: 0.014
-
Manzia TM, Angelico R, Toti L, Belardi C, Cillis A, Quaranta C, Tariciotti L, Katari R, Mogul A, Sforza D, Orlando G, Tisone G. The efficacy and safety of mammalian target of rapamycin inhibitors ab initio after liver transplantation without corticosteroids or induction therapy. Dig Liver Dis. 2016 Mar; 48(3):315-20.
Score: 0.014
-
Al-Shraideh Y, Farooq U, Farney AC, Palanisamy A, Rogers J, Orlando G, Buckley MR, Reeves-Daniel A, Doares W, Kaczmorski S, Gautreaux MD, Iskandar SS, Hairston G, Brim E, Mangus M, Stratta RJ. Influence of recipient age on deceased donor kidney transplant outcomes in the expanded criteria donor era. Clin Transplant. 2014 Dec; 28(12):1372-82.
Score: 0.013
-
Farney AC, Rogers J, Orlando G, al-Geizawi S, Buckley M, Farooq U, al-Shraideh Y, Stratta RJ. Evolving experience using kidneys from deceased donors with terminal acute kidney injury. J Am Coll Surg. 2013 Apr; 216(4):645-55; discussion 655-6.
Score: 0.011
-
Manzia TM, Angelico R, Baiocchi L, Toti L, Ciano P, Palmieri G, Angelico M, Orlando G, Tisone G. The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up. Transpl Int. 2013 Mar; 26(3):259-66.
Score: 0.011
-
Manzia TM, Angelico R, Toti L, Bellini MI, Sforza D, Palmieri G, Orlando G, Tariciotti L, Angelico M, Tisone G. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int. 2011 May; 24(5):461-8.
Score: 0.010
-
Lerut J, Mathys J, Verbaandert C, Talpe S, Ciccarelli O, Lemaire J, Bonaccorsi-Riani E, Vanthuyne V, Hetsch N, Roggen F, Reyck CD, Goffette P, Latinne D, Orlando G, Rahier J, Sempoux C, Wallemacq P, Laterre PF, Gianello P. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg. 2008 Dec; 248(6):956-67.
Score: 0.008
-
Martínez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, Benítez C, Pons JA, Parrilla P, Ramírez P, Bruguera M, Rimola A, Sánchez-Fueyo A. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest. 2008 Aug; 118(8):2845-57.
Score: 0.008
-
Lerut JP, Orlando G, Adam R, Schiavo M, Klempnauer J, Mirza D, Boleslawski E, Burroughs A, Sellés CF, Jaeck D, Pfitzmann R, Salizzoni M, Söderdahl G, Steininger R, Wettergren A, Mazzaferro V, Le Treut YP, Karam V. The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Ann Surg. 2007 Dec; 246(6):949-57; discussion 957.
Score: 0.008
-
Lerut J, Orlando G, Adam R, Sabbà C, Pfitzmann R, Klempnauer J, Belghiti J, Pirenne J, Thevenot T, Hillert C, Brown CM, Gonze D, Karam V, Boillot O. Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry. Ann Surg. 2006 Dec; 244(6):854-62; discussion 862-4.
Score: 0.007
-
Baiocchi L, Angelico M, De Luca L, Ombres D, Anselmo A, Telesca C, Orlando G, D'Andria D, Tisone G. Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after liver transplant in humans. Transpl Int. 2006 May; 19(5):389-95.
Score: 0.007
-
Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, Lionetti R, Anselmo A, Toti L, Angelico M. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol. 2006 Apr; 44(4):702-9.
Score: 0.007